SOLVAY PHARMACEUTICALS SA
Board
2 directors, 1 auditor, last change in 2024Director
since 09-12-2023
6-year term from 2023
also on the board of 1 other company
listed in the 2025 annual accounts, filed on 02-06-2026
Director
since 09-12-2023
6-year term from 2023
also on the board of 4 other companies
listed in the 2025 annual accounts, filed on 02-06-2026
Statutory auditor, permanent representative
current term since 30-05-2025
3-year term from 2025
listed in the 2025 annual accounts, filed on 02-06-2026
Mandates through the years
3 names, the dashed line is todayDirector
Director
Statutory auditor
BoardRest of the term
Mandates as a list
-
- Director, from 09-12-2023 to date
-
- Director, from 09-12-2023 to date
-
- Statutory auditor, from 25-05-2022 to date
With Starter you also see 19 former office holders in the mandate history.
See the plans →
Control
Consolidating parent
Equity €1.63bn
Profit €59.1m in 2025 (profit €227.0m in 2024)
Checked score
consolidates
This company
SOLVAY PHARMACEUTICALS SA
Equity €133,309
Profit €904,977 in 2025
Capital
- Capital
- €100,000
- Shares
- 4,746,441 in the 2025 annual accounts
- Contribution per share
- €0.02
- Equity per share
- €0.03 in 2025
- Source
- deed of 19-06-2023
Owners through the years
as the annual accounts name themOwners as a list
-
- 2007 to 2008: 0.02%
Source: shareholder structure in its own accounts, parent in its own accounts, lists of holdings in the owners' accounts
Articles of association
- Power of attorneyA power of attorney lets someone perform specific acts on the company's behalf.
- deed of 18-11-2016 (in French)
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Last Friday of May at 10:00deed of 19-06-2023 (in French)
Shareholders
2 ownersOwners 2
- LUparentSourceown accounts 2025100%
- consolidating parentEquity €1.63bn Profit of €59.1m in 2025 (profit of €227.0m in 2024) Checked scoreconsolidates
Capital transactions
Capital over time
- 19-06-2023 Capital stated in the deed · €100,000 · 4,746,441 shares
- 15-10-2019 Capital reduction of €47,706,452.39 · to €37,668,500.11 · to absorb losses
- 15-10-2019 Capital reduction of €37,568,500.11 · to €100,000 · repaid to the shareholders
- 03-02-2014 Capital reduction of €1,400,010,237.36 · to €85,374,952.50
- 11-10-2012 Capital reduction of €584,063,086.14 · to €2,334,998,128.86 · to absorb losses
- 11-10-2012 Capital reduction of €849,612,939 · to €1,485,385,189.86 · repaid to the shareholders